Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study

Starting soon · Not applicable

Conditions studied: Urinary Tract Infections, Urinary Tract Infections Caused by Drug-resistant Bacteria

In brief

This study is an investigator-initiated, single-center, exploratory clinical trial designed to evaluate the safety and efficacy of phage therapy in patients with urinary tract infections caused by drug-resistant bacteria. Eligible patients aged 18 to 65 years will receive the phage cocktail intervention according to a predefined dosage regimen, with a treatment course of 2 to 3 days and a follow-up period of 2 to 4 weeks after treatment. The primary outcome measures include the incidence of adverse events during treatment, the pathogen clearance rate, and the improvement of clinical symptoms (e.g., fever, local inflammation). The purpose of this study is to provide a scientific basis for the subsequent clinical application of this phage cocktail, and to explore a novel therapeutic option for patients with drug-resistant bacterial infections who have shown poor responses to conventional antibiotic therapy. All participants will undergo standardized medical monitoring throughout the trial, and their rights and safety will be fully protected by the Institutional Review Board (IRB) during the entire process.

Key facts

Study ID

NCT07382271

Run by

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

People needed

6

Starts

2026-02-01

Expected to finish

2026-08-01

Last updated by the study team

2026-02-02

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Aged 18-65 years old. 2. Patients with urinary tract infections caused by drug-resistant bacteria (based on drug susceptibility test results from our hospital or other Grade A tertiary hospitals).
• The pathogenic bacteria infected by the patient must meet one of the following conditions:
• Pathogenic bacteria are resistant to key antibiotics:
• ① Acinetobacter baumannii: carbapenem-resistant;
• Enterobacteriaceae (e.g., Klebsiella pneumoniae, Escherichia coli): carbapenem or cephalosporin-resistant;
• Pseudomonas aeruginosa: carbapenem-resistant;
• Enterococci: vancomycin-resistant; ⑤ Staphylococcus aureus: methicillin or vancomycin-resistant; ⑥ Stenotrophomonas maltophilia. Referenced to the WHO Bacterial Priority Pathogens List, 2024
• The pathogenic bacteria are sensitive to key antibiotics in vitro, but treatment with such antibiotics is ineffective or shows insignificant efficacy (the patient's target bacterial infection persists for 7 days or more, and the infection cannot be eradicated despite antibiotic administration during this period).
• The use of key antibiotics to which the pathogenic bacteria are sensitive is restricted (e.g., potential organ toxicity caused by the antibiotics, or the patient is allergic to such antibiotics).
• At least one lytic phage targeting the pathogenic bacteria can be screened out.
• The patient can tolerate the procedures of intravesical perfusion via urinary catheter, retrograde pyeloperfusion via ureteral catheter, or pyeloperfusion via percutaneous nephrostomy tube, and agrees to receive indwelling or intermittent catheterization during the treatment period.
• The subject and their family members (or legal guardian) have fully read and understood the relevant information, and signed the informed consent form.

You may not qualify if…

• 1. Bacterial infection controllable with conventional antibiotic therapy. 2. Presence of undrained urinary tract abscess or obstruction. 3. Severe renal impairment (eGFR <30 mL/min/1.73m²). 4. Concurrent organ failure (heart, liver, lung, etc.). 5. Severe autoimmune diseases. 6. No available phages active against the infecting pathogen. 7. Other conditions deemed unsuitable by the investigator.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.